Not a good buy right now for an impatient trader: price is in a clear downtrend and there’s no fresh catalyst or proprietary buy signal to justify stepping in.
Oversold RSI suggests a bounce is possible, but the broader trend (bearish moving averages) makes this a low-quality, high-risk entry.
With no recent news, neutral hedge/insider activity, and weak fundamentals (no revenue, larger losses), there isn’t a strong near-term reason to expect sustained upside.
Momentum: RSI_6 = 17.785 (deeply oversold) → bounce risk is elevated, but oversold can persist in a downtrend.
MACD: Histogram slightly above 0 (0.00422) but “positively contracting” → bullish momentum is weak/fading.
Levels: Current ~2.31 is sitting just above S1 = 2.289; a clean break below S1 increases risk toward S2 = 2.126. Upside resistance begins near Pivot 2.551 then R1 2.813.
Near-term pattern stats provided are modest (next week +4.55% expectation), but not strong enough to override the dominant downtrend.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Positioning: Put/Call OI ratio 0.77 (more call OI than put OI) → mildly bullish/less hedging pressure.
Activity: Option volume is effectively zero today (calls 0, puts 0) → sentiment signal is weak/low-conviction.
Volatility: IV percentile 18.4 (relatively low vs its own history), but the stock’s historical volatility is extremely high, implying price can move sharply even without options flow confirmation.
Technical Summary
Sell
9
Buy
3
Positive Catalysts
can trigger short-covering or a reflex bounce, especially if 2.289 support holds.
No news in the past week → no visible event-driven catalyst to change the trend.
If support at ~2.289 fails, the next technical magnet is ~2.126 (S2), leaving near-term downside room.
Trading trends: hedge funds and insiders are neutral (no supportive accumulation signal).
No recent congress trading data and no influential-figure buying/selling signal provided.
Financial Performance
Latest quarter: 2025/Q3.
Revenue: 0 (no operating revenue base).
Profitability: Net income -1,992,790 (worse YoY: -29.37%).
EPS: -1.23 (worse YoY: -64.35%).
Takeaway: losses are expanding and there is no revenue growth runway visible in the snapshot—fundamentals do not support an “impatient buy-the-dip” approach.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating or price target change data was provided, so there’s no confirmable positive Wall Street trend to lean on.
Pros (typical bull case): small-cap biotech optionality can re-rate quickly on trial/corporate updates.
Cons (current data-driven view): absent catalysts + deteriorating earnings metrics + downtrend means the risk/reward is not attractive right now.
Wall Street analysts forecast ACXP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACXP is 30.5 USD with a low forecast of 30 USD and a high forecast of 31 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast ACXP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACXP is 30.5 USD with a low forecast of 30 USD and a high forecast of 31 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.060
Low
30
Averages
30.5
High
31
Current: 2.060
Low
30
Averages
30.5
High
31
H.C. Wainwright
H.C. Wainwright
NULL -> Buy
upgrade
$8 -> $31
AI Analysis
2025-08-12
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$8 -> $31
AI Analysis
2025-08-12
upgrade
NULL -> Buy
Reason
H.C. Wainwright adjusted the firm's price target on Acurx to $31 from $8 and keeps a Buy rating on the shares following the recent 1-for-20 reverse stock split. The firm believes the company's lead asset ibezapolstat is making steady progress as it prepares to enter Phase 3 evaluation.
H.C. Wainwright
NULL
to
Buy
initiated
$8
2025-05-15
Reason
H.C. Wainwright
Price Target
$8
2025-05-15
initiated
NULL
to
Buy
Reason
H.C. Wainwright assumed coverage of Acurx with a Buy rating and $8 price target. Acurx is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria, the analyst tells investors in a research note. The firm believes the company is "flying under the radar with investors" into a "paradigm shifting moment in anti-infectives."
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ACXP
